Samsara BioCapital, LLC ARTV — ARTIVA BIOTHERAPEUTICS INC

Ownership history in Samsara BioCapital, LLC  ·  5 quarters on record

AI Ownership Summary

Samsara BioCapital, LLC reported ARTIVA BIOTHERAPEUTICS INC (ARTV) in 5 quarterly 13F filings from 2024 Q3 through 2026 Q2. Peak portfolio weight reached 0.87% in 2024 Q3. The latest visible filing shows ARTV at 0.76% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this ARTV ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Samsara BioCapital, LLC's position in ARTIVA BIOTHERAPEUTICS INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q2

ARTV was reported at 0.76% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.87% in 2024 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2024 Q3 to 2026 Q2

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

ARTV stock page Samsara BioCapital, LLC fund profile Samsara BioCapital, LLC full holdings
How Samsara BioCapital, LLC held ARTV — position size vs. price
% of Fund (quarterly)    ARTV price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 5 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q2 ADDED — — — 954,861 +663,195 +227.4% 0.76% $9.3M 2026-08-14 $11.45
2025 Q2 UNCHANGED — — — 291,666 — 0% 0.09% $440K 2025-08-14 $2.70
2025 Q1 UNCHANGED — — — 291,666 — 0% 0.16% $875K 2025-05-15 $2.13
2024 Q4 UNCHANGED — — — 291,666 — 0% 0.40% $2.9M 2025-02-14 $4.44
2024 Q3 INITIATED — — — 291,666 — — 0.87% $4.5M 2024-11-14 $10.51

🏢 Other funds also holding ARTV

As of 2026 Q2 — sorted by position size

5AM Venture Management, LLC 3Y 7.93% Propel Bio Management, LLC 3.54% Revelation Capital Management, LLC 2.65% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 1.76% RA CAPITAL MANAGEMENT, L.P. 3Y 7Y 1.51% KVP Capital Advisors, LP 1.42% Blue Owl Capital Holdings LP 3Y 1.28% Caligan Partners LP 3Y 0.79% Venrock Adviser, LLC 3Y 0.6% SILVERARC CAPITAL MANAGEMENT, LLC 3Y 0.53%

FAQ About Samsara BioCapital, LLC and ARTV

These are the practical questions this page is built to answer before you even open the full history table.

How long has Samsara BioCapital, LLC reported owning ARTV?

Samsara BioCapital, LLC reported ARTV across 5 quarterly 13F filings, from 2024 Q3 through 2026 Q2.

What was the largest reported ARTV position in Samsara BioCapital, LLC's portfolio?

The largest reported portfolio weight for ARTV was 0.87% in 2024 Q3.

What is the latest reported ARTV position on this page?

The most recent filing on this page is 2026 Q2, when Samsara BioCapital, LLC reported 954,861 shares, equal to 0.76% of portfolio, with an estimated market value of $9.3M.

What does the chart on this ARTV ownership page compare?

The chart compares Samsara BioCapital, LLC's quarterly ARTV portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

← Back to Samsara BioCapital, LLC Holdings